What the?

[anonymous]

if this is old news, I'm sorry. But what is going on here?

Collaboration Update

Shire announced that SHP-465 for the treatment of ADHD is expected to be launched in the second half of 2017 after SHP-465 receives FDA approval, which is expected on or around June 20, 2017. Based on the agreement between Supernus and Shire, Shire will pay to Supernus a single-digit percentage royalty on net sales of the product.

 

[anonymous]

http://www.in-pharmatechnologist.com/Regulatory-Safety/Supernus-buys-Shire-Labs-drug-making-outfit

 

[anonymous]

Shire will pay to Supernus a single-digit percentage royalty on net sales of the product.

Let me take a guess at what that single digits is... 9%? Bet u I'm right. Feels good that our bonus money for launching the new product is going to Supernus... that is motivating...more smart negotiations by Shire. Check out their Dermagraft deal. That was smart Flem and Per.